The key factors driving the growth of PDX Models Market include the
growing demand for personalized medicine, continuous support for cancer
research from the public as well as private sectors, and growth in the number
of R&D activities in the pharmaceutical industry. The growing use of
humanized PDX models is posing a lucrative opportunity in this market.
What the market looks like?
The PDX models market is expected to reach USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017, at a CAGR of 16.7%.
Tumor Type:
The gastrointestinal tumors segment is expected to account for the largest share of the global PDX models market. The respiratory tumors segment, on the other hand, is expected to be the fastest-growing segment during the forecast period. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment as lung cancer is the leading cause of cancer-related deaths across the globe.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
Pre Clinical Drug Development and Basic Cancer Research:
The preclinical drug development and basic cancer research segment is expected to account for the largest share of the global PDX models market. The large share of this segment can be mainly attributed to the increasing number of research activities in the field of oncology drug research.
North America and Europe to Dominate The PDX Models Market:
North America accounted for the largest share of the PDx models market in 2017, followed by Europe. The large share of the North American PDX models market can be attributed to the growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to strong research expenditure and the well-structured CRO industry in China, growth in biomedical & medical research in Japan, rising pharmaceutical R&D expenditure in India, and rising translational and biomedical research in Singapore.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251
Key Players:
The key players in the PDX models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).
What the market looks like?
The PDX models market is expected to reach USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017, at a CAGR of 16.7%.
Tumor Type:
The gastrointestinal tumors segment is expected to account for the largest share of the global PDX models market. The respiratory tumors segment, on the other hand, is expected to be the fastest-growing segment during the forecast period. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment as lung cancer is the leading cause of cancer-related deaths across the globe.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
Pre Clinical Drug Development and Basic Cancer Research:
The preclinical drug development and basic cancer research segment is expected to account for the largest share of the global PDX models market. The large share of this segment can be mainly attributed to the increasing number of research activities in the field of oncology drug research.
North America and Europe to Dominate The PDX Models Market:
North America accounted for the largest share of the PDx models market in 2017, followed by Europe. The large share of the North American PDX models market can be attributed to the growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to strong research expenditure and the well-structured CRO industry in China, growth in biomedical & medical research in Japan, rising pharmaceutical R&D expenditure in India, and rising translational and biomedical research in Singapore.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251
Key Players:
The key players in the PDX models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).
Comments
Post a Comment